ClinicalTrials.gg
Active, not recruitingNCT06523465STOP-PAUpdated Nov 16, 2026

Statin Combined With Amlodipine Treats Primary Aldosteronism

A Phase 4 interventional study of Simvastatin combined with Amlodipine besylate and Simvastatin combined with Spironolactone and Amlodipine besylate. in Primary Aldosteronism, Statin and Mineralocorticoid Receptor Antagonist, sponsored by Third Military Medical University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Third Military Medical University · Phase 4, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hyperaldosteronism by Third Military Medical University — 3 open to participants now, 4 under way, none of them phase 3. Hyperaldosteronism · Third Military Medical University.

Started
2024
the only one that year
Phase 4
Only one
of the 10
Registered
8th of 10
by date

Among the 10 studies in Hyperaldosteronism by Third Military Medical University, this one is the only one that started in 2024, is the only one in phase 4, and was the 8th registered.

Hyperaldosteronism

201 studies on the registry are indexed under Hyperaldosteronism; 91 are open to participants now.

Browse Hyperaldosteronism studies →

Open to participants now

3 of the 10 studies in Hyperaldosteronism by Third Military Medical University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 68 Hyperaldosteronism studies recruiting now, 22 (32%) set no upper age limit and 30 (44%) stop at 75 or younger; 6 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hyperaldosteronism by Third Military Medical University, or all of them as a file.
02

Study summary

The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.

03

Conditions studied

  • Primary Aldosteronism
  • Statin
  • Mineralocorticoid Receptor Antagonist
  • Hypertension

Keywords

  • primary aldosteronism
  • hypertension
  • Statin
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of primary aldosteronism

Exclusion criteria

Exclusion Criteria:

  • Allergy to drugs in this study
  • Pregnancy
  • Severe liver and kidney dysfunction
  • Mental illness
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Simvastatin combined with Amlodipine besylate

    after 1:1 randomization, 60 patients with primary aldosteronism were treated with Simvastatin combined with Amlodipine besylate for 6 months

    Drug: Simvastatin combined with Amlodipine besylate

  • Experimental
    Simvastatin combined with Spironolactone and Amlodipine besylate.

    after 1:1 randomization, 60 patients with primary aldosteronism were treated with Simvastatin combined with Spironolactone and Amlodipine besylate for 6 months

    Drug: Simvastatin combined with Spironolactone and Amlodipine besylate.

  • Experimental
    Amlodipine besylate combined with Spironolactone

    after 1:1 randomization, 60 patients with primary aldosteronism were treated with Amlodipine besylate combined with Spironolactone for 6 months

    Drug: Amlodipine besylate combined Spironolactone

Interventions

  • DrugSimvastatin combined with Amlodipine besylate

    Drug pages: SimvastatinStudies of SimvastatinSimvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    6-month treatment of Simvastatin combined with Amlodipine besylate

  • DrugSimvastatin combined with Spironolactone and Amlodipine besylate.

    6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.

  • DrugAmlodipine besylate combined Spironolactone

    6-month treatment of Amlodipine besylate combined with Spironolactone

06

What researchers measure

Primary outcomes

  1. changes in plasma aldosterone levels

    blood samples are collected at baseline and 6 months after treatment to measure plasma aldosterone levels, and compare between groups and within groups (pg/ml)

    Time frame: 6 month

Secondary outcomes

  1. changes in 24-hour urinary aldosterone levels

    24 hours urine are collected at baseline and 6 months after treatment to measure 24-hour urinary aldosterone, and compare between groups and within groups(pmol/24h)

    Time frame: 6 month

  2. changes in office blood pressure

    Record office blood pressure at baseline and at follow-up after medical treatment (mmHg), and compare between groups and within groups

    Time frame: 6 month

  3. changes in serum potassium levels

    blood samples are collected at baseline and 6 months after treatment to measure serum potassium levels, and compare between groups and within groups (mmol/L)

    Time frame: 6 month

  4. changes in serum renin level

    blood samples are collected at baseline and 6 months after treatment to measure serum renin levels, and compare between groups and within groups (mU/L)

    Time frame: 6 month

  5. changes in plasma cholesterol levels

    blood samples are collected at baseline and 6 months after treatment to measure plasma cholesterol levels, and compare between groups and within groups (mmol/L)

    Time frame: 6 month

  6. changes in blood glucose

    blood samples are collected at baseline and 6 months after treatment to measure blood glucose, and compare between groups and within groups (mmol/L)

    Time frame: 6 month

07

Study locations

1 site
  • No. 10 Changjiang River Branch, Yuzhong District,Chongqing, China
    Chongqing, Chongqing Municipality 400042, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2024 (actual). Primary completion is estimated for Nov 2026, 26 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Dec 2025 → Nov 2026 and completion Sep 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Jul 26, 2024
StartActual
Sep 10, 2024
Primary completionEst.
Nov 15, 2026was Dec 2025
CompletionEst.
Nov 15, 2026was Sep 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 16, 2026
Sites
1 site added, 1 site removed
Show site
  • No. 10 Changjiang River Branch, Yuzhong District,Chongqing, China · Chongqing, China
Show 1 removed
  • No. 10 Changjiang River Branch, Yuzhong District,Chongqing, China · Chongqing, China
Nov 16, 2026
Primary completion
Dec 30, 2025→Nov 15, 2026
Nov 16, 2026
Study completion
Sep 30, 2026→Nov 15, 2026
Nov 16, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • Removedchanges in 24-hour urinary aldosterone levelsTime frame: 6 month
Nov 16, 2026
Secondary outcomes
1 edited, 1 added
What changed in the outcomes
  • Editedchanges in office blood pressure and home blood pressureTime frame: 6 month
  • Addedchanges in 24-hour urinary aldosterone levelsTime frame: 6 month
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • No. 10 Changjiang River Branch, Yuzhong District,Chongqing, China · Chongqing, China
    Show 1 removed
    • No. 10 Changjiang River Branch, Yuzhong District,Chongqing, China · Chongqing, China
    Primary completion Dec 30, 2025→Nov 15, 2026
    Study completion Sep 30, 2026→Nov 15, 2026
    Primary outcomes 1 removed
    What changed in the outcomes
    • Removedchanges in 24-hour urinary aldosterone levelsTime frame: 6 month
    Secondary outcomes 1 edited, 1 added
    What changed in the outcomes
    • Editedchanges in office blood pressure and home blood pressureTime frame: 6 month
    • Addedchanges in 24-hour urinary aldosterone levelsTime frame: 6 month
    + 4 other changes: identifiers, verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06523465
Lead sponsor
Third Military Medical University
Responsible party
Zhiming Zhu (Department of Hypertension and Endocrinology, Third Military Medical University) — Principal investigator
First posted
Jul 26, 2024
Start date
Sep 10, 2024
Primary completion
Nov 15, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Nov 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Simvastatin · Amlodipine

Start the discussion